Last Updated : June 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Truvada | Emtricitabine/tenofovir disoproxil fumarate | HIV-1 infection, pre-exposure prophylaxis | Reimburse with clinical criteria and/or conditions | Complete | ||
Truvada | Emtricitabine/tenofovir disoproxil fumarate | HIV infection | List with clinical criteria and/or conditions | Complete | ||
Truvada | Emtricitabine/tenofovir disoproxil fumarate | HIV infection | List with clinical criteria and/or conditions | Complete | ||
Truxima | Rituximab | Cancelled | ||||
Tudorza Genuair | Aclidinium bromide | Chronic Obstructive Pulmonary Disease | List with criteria/condition | Complete | ||
Tukysa | tucatinib | Advanced or Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Twynsta | Telmisartan / Amlodipine | Hypertension | Cancelled | |||
Twynsta | Telmisartan/ Amlodipine | Hypertension | List | Complete | ||
Tykerb (in combination with Letrozole) | Lapatinib | Metastatic Breast Cancer | Do not reimburse | Complete | ||
Tysabri | natalizumab | Multiple Sclerosis, relapsing-remitting | Withdrawn | |||
Tysabri | Natalizumab | Multiple Sclerosis, relapsing-remitting | Do not list | Complete | ||
Tysabri | Natalizumab | Multiple Sclerosis, relapsing-remitting | List with clinical criteria and/or conditions | Complete | ||
Uloric | Febuxostat | Gout | List with clinical criteria and/or conditions | Complete | ||
Ultibro Breezhaler | Indacaterol/glycopyrronium | Chronic obstructive pulmonary disease | List with criteria/condition | Complete | ||
Ultomiris | ravulizumab | Neuromyelitis optica spectrum disorder (NMOSD) | Reimburse with clinical criteria and/or conditions | Complete | ||
Ultomiris | ravulizumab | Atypical hemolytic uremic syndrome | Reimburse with clinical criteria and/or conditions | Complete | ||
Ultomiris | ravulizumab | Paroxysmal nocturnal hemoglobinuria | Reimburse with clinical criteria and/or conditions | Complete | ||
Ultomiris | ravulizumab | AChR antibody-positive generalized Myasthenia Gravis | Do not reimburse | Complete | ||
Ultomiris | ravulizumab | Generalized Myasthenia Gravis | Active | |||
Unituxin | Dinutuximab | Neuroblastoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Unituxin | dinutuximab | Neuroblastoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Uplizna | inebilizumab | Neuromyelitis optica spectrum disorders (NMOSD) | Reimburse with clinical criteria and/or conditions | Active | ||
Uptravi | Selexipag | Pulmonary arterial hypertension (WHO class II and III) | Reimburse with clinical criteria and/or conditions | Complete | ||
Vabysmo | faricimab | Retinal vein occlusion | Pending | |||
Vabysmo | faricimab | Diabetic Macular Edema | Reimburse with clinical criteria and/or conditions | Complete |